Navigation Links
Novel protein may help detect Lou Gehrig's disease and dementia, Mayo Clinic finds
Date:2/12/2013

JACKSONVILLE, Fla. Researchers at Mayo Clinic have discovered an abnormal protein that accumulates in the brains of many patients affected with two common neurodegenerative disorders amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease, and frontotemporal dementia. They say their findings have uncovered a potentially new therapeutic target and biomarker that would allow clinicians to confirm diagnosis of the diseases. The study is published online today in the journal Neuron.

The Mayo research team, led by scientists at Mayo Clinic's campus in Florida, discovered the abnormal protein pathology that they call C9RANT. An error in the highly regulated cellular process through which proteins are generated causes the abnormal production of C9RANT. The team developed an antibody that can detect the specific, insoluble protein that clumps together and is present in patients with mutations in the C9ORF72 gene, which was previously identified by Mayo Clinic researchers as the most common genetic cause of ALS and frontotemporal dementia.

"This new finding sheds light on how the mutation causes these disorders, and it provides us with a marker that helps us track disease progression in patients with this disorder and potentially combat the disease," says senior author Leonard Petrucelli, Ph.D., a molecular neuroscientist and director of the Department of Neuroscience at Mayo Clinic in Florida.

If it is shown that, as suspected, these protein clumps are the cause of neuronal death and toxicity in these diseases, it may be possible to design therapies to break the clumps apart or to prevent the protein from accumulating in the first place, Dr. Petrucelli says.

Because the protein is found throughout the central nervous system in patients with ALS and frontotemporal dementia but not in other neurodegenerative diseases the researchers hope that in the future it can be tested through a spinal tap.

After Alzheimer's disease, frontotemporal dementia is the most common form of early onset neurodegenerative dementia. It is characterized by changes in personality, behavior and language due to loss of gray matter in the brain's frontal lobe. ALS destroys motor neuron cells that control essential muscle activity such as speaking, walking, breathing and swallowing.

This new discovery stems from a key finding, reported simultaneously in 2011 by Mayo researchers and scientists from the National Institutes of Health, that an unusual mutation a short DNA sequence repeated hundreds to thousands of times was found in almost 12 percent of familial frontotemporal dementia and more than 22 percent of familial ALS samples studied.


'/>"/>
Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Novel radiation therapy method shortens prostate cancer treatment time
2. Novel gene-searching software improves accuracy in disease studies
3. New Novel Looks at British NHS from the Inside
4. Fox Chase researchers discover novel role of the NEDD9 gene in early stages of breast cancer
5. IRSF awards $1.5 million for novel basic and translational research programs
6. Nobel laureate James Watson publishes novel hypothesis on curing late-stage cancers
7. PolyU Researchers Develop Novel Treatment for People with Hemiplegic Arms
8. 2 novel treatments for retinitis pigmentosa move closer to clinical trials
9. Neurological Wellness Center's Novel Neuro-Inflammation Inhibition Procedure that Induces Rapid Recovery from Alzheimer's, Stroke and Brain Injury is Now Being Taught in a Newly Released Video
10. Novel test identifies patients most likely to benefit from ALK inhibition therapy
11. Novel drug therapy targets aggressive form of non-Hodgkins lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... ... 19, 2017 , ... "At your fingertips" electronic access to ... the Delaware Health Information Network (DHIN) have partnered to improve connectivity of this ... information exchange, DHIN stores and shares real-time health data for more than 2 ...
(Date:2/18/2017)... Waltham, Massachusetts (PRWEB) , ... February 17, 2017 ... ... be the leading source of disruptive innovation in the industry, according to the ... Insights Reports are based on surveys of the NEJM Catalyst Insights Council, a ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, Joette White, has ... Life Radio network. The episode, which was posted this week, features a 30-minute ... led to Park Cities Pet Sitter’s being awarded the 2017 National Association of Professional ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... Smiles by ... Shopping Center in Davidson, NC. Dr. Brian Seese leads the practice as a skilled ... services under one roof. Smiles by Seese serves patients of all ages with excellence ...
(Date:2/17/2017)... ... February 17, 2017 , ... Wells Pharmacy ... electronic prescribing of controlled and non-controlled substances plus the ability to manage orders ... the United States now accept electronic prescriptions, according to the Office of the ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , Feb. 17, 2017 Theravance ... Biopharma" or the "Company") today announced the presentation ... potent, and orally administered pan-Janus kinase (JAK) inhibitor ... th Congress of the European Crohn,s and ... Company reported further data from its completed Phase ...
(Date:2/17/2017)... 17, 2017   Risperdal lawsuits involving gynecomastia (male ... with use of the atypical antipsychotic medication continue to ... Court of Common Pleas, where the state,s Risperdal docket ... to a notice posted on the Court,s website ... on March 9, 2017 at 11:00 a.m. (In Re: ...
(Date:2/17/2017)... YORK , Feb. 17, 2017  BioDigital, ... today the partnership of their 3D body mapping ... healthcare IT.  The new integration will be used ... an interactive model of the human body. BioDigital ... saves clinicians time, while also increasing the precision ...
Breaking Medicine Technology: